|
|
艾拉莫德治疗类风湿性关节炎的诊疗进展
|
Abstract:
艾拉莫德(iguratimod, IGU)是一种改善风湿病情类药物，具有抑制炎症、减少骨破坏等作用，在类风湿性关节炎治疗中取得了良好的疗效。在临床试验中，IGU被证明优于安慰剂，其与其他抗风湿药物联合治疗使得疾病活跃度显著改善。在这篇综述中，我们总结了IGU的作用机制及其临床有效性和安全性的研究现状。
Iguratimod (IGU) is a kind of rheumatoid drug, which has the effect of inhibiting inflammation and reducing bone destruction, and has achieved good curative effect in the treatment of rheumatoid arthritis. In clinical trials, IGU was shown to be superior to placebo, and its combination with other anti-rheumatic drugs resulted in a significant improvement in disease activity. In this review, we summarize the current status of research on the mechanism of action of IGU and its clinical efficacy and safety.
| [1] | Smolen, J.S., Aletaha, D. and Mcinnes, I.B. (2016) Rheumatoid Arthritis. The Lancet, 388, 2023-2038.
https://doi.org/10.1016/S0140-6736(16)30173-8 |
| [2] | Burmester, G.R. and Pope, J.E. (2019) Novel Treatment Strategies in Rheumatoid Arthritis. |
| [3] | Blair, H.A. and Deeks, E.D. (2017) Abatacept: A Review in Rheumatoid Ar-thritis. Drugs, 77, 1221-1233.
https://doi.org/10.1007/s40265-017-0775-4 |
| [4] | 邹耀威, 连舒燕, 陈楚涛, 等. 类风湿关节炎患者功能受限特征及相关因素分析[J]. 中华内科杂志, 2022, 61(2): 193-199. |
| [5] | 中华医学会风湿病学分会. 2018中国类风湿关节炎诊疗指南[J]. 中华内科杂志, 2018, 57(4): 242-251. |
| [6] | Aletaha, D., Neogi, T., Silman, A.J., et al. (2010) Rheumatoid Arthritis Classification Criteria: An American College of Rheumatology/European League against Rheuma-tism Collaborative Initiative. Arthritis & Rheumatology, 62, 2569-2581.
https://doi.org/10.1002/art.27584 |
| [7] | 周云杉, 王秀茹, 安媛, 等. 全国多中心类风湿关节炎患者残疾及功能受限情况的调查[J]. 中华风湿病学杂志, 2013, 17(8): 526-532. |
| [8] | 耿研, 谢希, 王昱, 等. 类风湿关节炎诊疗规范[J]. 中华内科杂志, 2022, 61(1): 51-59. |
| [9] | Maruotti, N., Cantatore, F.P. and Ribatti, D. (2014) Putative Effects of Potentially Anti-Angiogenic Drugs in Rheumatic Diseases. European Journal of Clinical Pharmacology, 70, 135-140. https://doi.org/10.1007/s00228-013-1605-6 |
| [10] | Tanaka, K. and Yamaguchi, T. (2012) Pharmacological Properties and Clinical Efficacy of the Synthetic Anti-Rheumatic Drug, Iguratimod (Kolbet？/Careram？). Nihon Yakurigaku Zasshi, 140, 285-292.
https://doi.org/10.1254/fpj.140.285 |
| [11] | Mucke, H.A. (2012) Iguratimod: A New Disease-Modifying Antirheu-matic Drug. Drugs Today (Barc), 48, 577-586.
https://doi.org/10.1358/dot.2012.48.9.1855758 |
| [12] | 张源潮, 王峰, 王威严, 等. 类风湿关节炎治疗新药艾拉莫德[J]. 世界临床药物, 2013, 34(2): 65-69. |
| [13] | Amiche, M.A., Albaum, J.M., Tadrous, M., et al. (2016) Fracture Risk in Oral Glucocorticoid Users: A Bayesian Meta-Regression Leveraging Control Arms of Osteoporosis Clinical Tri-als. Osteoporosis International, 27, 1709-1718.
https://doi.org/10.1007/s00198-015-3455-9 |
| [14] | Boyce, B.F. and Xing, L. (2007) Biology of RANK, RANKL, and Osteoprotegerin. Arthritis Research & Therapy, 9, S1. https://doi.org/10.1186/ar2165 |
| [15] | Blavnsfeldt, A.G., De Thurah, A., Thomsen, M.D., et al. (2018) The Effect of Glucocorticoids on Bone Mineral Density in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials. Bone, 114, 172-180. https://doi.org/10.1016/j.bone.2018.06.008 |
| [16] | Hienz, S.A., Paliwal, S. and Ivanovski, S. (2015) Mechanisms of Bone Resorption in Periodontitis. Journal of Immunology Research, 2015, Article ID: 615486. https://doi.org/10.1155/2015/615486 |
| [17] | Yi, P., Park, J.S. and Melton, D.A. (2017) Retraction Notice to: Beta-trophin: A Hormone That Controls Pancreatic β Cell Proliferation. Cell, 168, Article No. 326. https://doi.org/10.1016/j.cell.2016.12.017 |
| [18] | Christensen, A.D., Skov, S., Kvist, P.H. and Haase, C. (2015) De-pletion of Regulatory T Cells in a Hapten-Induced Inflammation Model Results in Prolonged and Increased Inflammation Driven by T Cells. Clinical and Experimental Immunology, 179, 485-499. https://doi.org/10.1111/cei.12466 |
| [19] | 王清泰, 肖燕萍, 章尤权, 等. 艾拉莫德对类风湿关节炎患者Th17细胞与Treg细胞失衡的调节作用[J]. 医疗装备, 2018, 31(10): 6-8. |
| [20] | Mimori, T., Harigai, M., Atsumi, T., et al. (2017) Safety and Effectiveness of 24-Week Treatment with Iguratimod, a New Oral Disease-Modifying Antirheumatic Drug, for Patients with Rheumatoid Arthritis: Interim Analysis of a Post-Marketing Surveillance Study of 2679 Patients in Japan. Modern Rheumatology, 27, 755-765.
https://doi.org/10.1080/14397595.2016.1265695 |
| [21] | Mimori, T., Harigai, M., Atsumi, T., et al. (2019) Safety and Effectiveness of Iguratimod in Patients with Rheumatoid Arthritis: Final Report of a 52-Week, Multicenter Postmarketing Surveillance Study. Modern Rheumatology, 29, 314-323.
https://doi.org/10.1080/14397595.2018.1460230 |
| [22] | 高晶月, 刘维. 艾拉莫德治疗类风湿关节炎的研究进展[J]. 风湿病与关节炎, 2017, 6(3): 69-72+76. |
| [23] | 施卫民, 刘棒, 王文琴. 艾拉莫德联合改善病情的抗风湿药治疗类风湿关节炎合并骨质疏松的疗效分析[J]. 临床药物治疗杂志, 2023, 21(2): 31-35. |
| [24] | 叶仿武, 朱峪英, 吴理扬, 等. 艾拉莫德联合甲氨蝶呤治疗难治性类风湿关节炎的临床观察[J]. 临床医学研究与实践, 2016, 1(8): 24. |
| [25] | Hara, M., Ishiguro, N., Katayama, K., et al. (2014) Safety and Efficacy of Combination Therapy of Iguratimod with Methotrexate for Patients with Active Rheumatoid Arthritis with an Inadequate Response to Methotrexate: An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Trial. Modern Rheumatology, 24, 410-418.
https://doi.org/10.3109/14397595.2013.843756 |
| [26] | 韩玉艳, 黄露露, 杨梦妮, 等. 艾拉莫德或甲氨蝶呤联合来氟米特治疗活动性老年类风湿关节炎104例[J]. 中国新药杂志, 2023, 32(17): 1749-1755. |
| [27] | 田真. 艾拉莫德联合来氟米特治疗老年类风湿关节炎的临床疗效评估[D]: [硕士学位论文]. 百色: 右江民族医学院, 2020. |
| [28] | 戴璐, 宋欣丽, 邱肖明, 等. 艾拉莫德联合来氟米特治疗中、重度老年活动性类风湿性关节炎的效果观察[J]. 实用临床医药杂志, 2019, 23(3): 73-77. |
| [29] | 牛敏, 闫美茜, 高洁, 等. 艾拉莫德与来氟米特治疗类风湿关节炎对患者骨代谢及血清IgA、IgG、IgM的影响[J]. 海南医学, 2021, 32(10): 1252-1255. |
| [30] | 王万红. 来氟米特联合艾拉莫德治疗活动性类风湿性关节炎的疗效及安全性[J]. 中国处方药, 2020, 18(9): 98-99. |
| [31] | 刘圣徽, 张细凤, 闻秀珍, 等. 艾拉莫德配合来氟米特对中重度活动性类风湿关节炎患者关节功能及改良类风湿活动指数的影响[J]. 吉林医学, 2023, 44(12): 3487-3490. |
